{'fraction_non_alphanumeric': 0.030759766225776683, 'fraction_numerical': 0.014764687788372808, 'mean_word_length': 4.626297577854671, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Functionality and Clinical Effects of Anti-Cov2 Vaccines (Aka Mrna) And Integration on Mitochondrial DNA

1. This issue would require many pages, but it is briefly described here for easier understanding 2. The writer refers to the Molecular Biology Experts and to reading the copious literature on the proteins/ enzymes found in mRNA vaccines using the BLASTP approach (Appendix 1) 3. The reference literature, apart from being written in English, is also worded in an extremely technical style 4. They are given a specific functional sequence, aimed at the incorporation and expression of vaccine mRNA into the genome of the mitochondria (mtDNA) 5. The vaccine mRNA does not refer to the segment relating to the Spike protein, but to the entire viral genome 6. Therefore, the Ribosomes are not the final destination of the vaccine mRNA; instead, the Mitochondria are actually the seat of a DNA, accommodating the SARS-Cov2 genome in the same way as it does in the nuclear genome. 7. Both the Mitochondria and Ribosomes are located in the Ergastoplasm and are separated from the cytosol by an oxidation/reduction barrier 'in mV' (= one thousand times) three times higher than that of the cytosol. 8. Article from Science: Oxidized Redox State of Glutothiane in the Endoplasmic reticulum - 11 September 1992 volume 257, page 1496:15026 9. Thus only an mRNA that exits from both the nuclear and mitochondrial genomes has the enzyme support that allows it to reach the ribosomes, overcoming the resistance of the oxidation/reduction barrier 10. If this were not the case, RNA viruses would not lengthen the pathway, integrating before the genome and then reaching the ribosomes again as mRNA (it must be said that, in an RNA virus, the genomic RNA is the same as the RNA coming out of the nucleus), but would immediately aim to reach the ribosomes, as RNA vaccines are said to do. 11. Nano technologies are said to be the architects of this miraculous and rapid rush to the ribosomes of vaccine mRNA 12. These nano-technologies are nothing more than a sequence of proteins/enzymes - undeclared - which are now described here in their function in the main patterns 13. a) ryanodine receptorby managing the Ca++ ion flux channels, it first depolarises the mitochondrial membrane, which is the first step for mRNA entry and then it lowers the oxidative/reductive level of the ergastoplasm, activating an osmotic "Δ" (= delta-difference) around the mitochondria, releasing the protonated ions (=H + ) present in the virtual space of the two sheets forming the mitochondrial membrane into the area. 14. b) ABC transporter - ATP - binding protein By binding to ATP, it allows vaccine RNA to enter the mitochondria 15. c) Epical complex lysine methyltran spherase By providing mobility for the entering mRNA, it allows to reach the stretch of mitochondrial DNA most suitable for integration 16. d) DDLS - Typ - integrase/transpasase It simultaneously does the work performed before by reverse transcriptase and integrase, and then inserts a viral genome RNA, similar to the genomic RNA in RNA viruses, into the mitochondrial genome. 17. e) Pullulanase The hydrolysis of the (1 → 6) X - D glucoside bonds of mitochondrial DNA paves the way for the action of the